Sarah advises medical products companies developing and manufacturing pharmaceuticals, biologics, and medical devices on issues where FDA regulatory and compliance matters intersect with strategic business decision-making. She specifically focuses on providing FDA regulatory and compliance counsel to medical products clients on a variety of matters, including Good Clinical Practice and clinical trials, pharmacovigilance, medical communications and health care economic information, Good Manufacturing Practice (drugs and medical devices), advertising and promotion, patient support programs, and ClinicalTrials.gov registration and reporting. She has also written and spoken extensively on clinical trial modernization and diversity, in addition to the implications of the recent Food and Drug Omnibus Reform Act (FDORA) and current draft FDA guidance.